Gold Prices Slip as Stronger Dollar and Iran Peace Talk Uncertainty Weigh on Market 
SQM Q1 Profit More Than Doubles as Lithium Prices Surge 
S&P 500 Hits Record High as Tech Rally Slows Amid Iran Peace Uncertainty 
Dow Hits Record High as Healthcare and Consumer Stocks Lead Wall Street Rally 
Dell Raises 2027 Revenue Forecast as AI Server Demand Drives Record Quarterly Results 
US Quantum Stocks Surge After $2 Billion Government Investment 
CTOC Goes Live on Bitget Wallet Trading, Expanding Global Access to AI-Powered Healthcare Data Ecosystem 
Universal Music Group Rejects Pershing Square Takeover Proposal 
Salesforce Q1 FY2027 Earnings Beat Expectations Despite Soft Q2 Revenue Outlook 
Samsung to Invest $1.5 Billion in Vietnam Semiconductor Testing Plant by 2027 
Blue Origin New Glenn Rocket Explodes During Launch Pad Test, Delaying Space Ambitions 
Tokyo Inflation Cools in May, Supporting BOJ’s Cautious Rate Hike Path 
Nikkei Hits Record High as AI Chip Stocks Power Japan Market Rally 
US Imposes Fresh Iran Oil Sanctions Despite Progress on Ceasefire Talks 
Asian Markets Slide as New U.S. Strikes on Iran Spark Investor Caution 
Wall Street Hits New Highs as U.S.-Iran Ceasefire Talks Boost Market Sentiment 
Marvell Stock Rises After Record Q1 FY2027 Earnings Fueled by AI Demand 
NGeneBio, a leading company in molecular diagnostics (MDx) and companion diagnostics (CDx) in South Korea, announced it had established its new subsidiary in the United States. The company said on Monday, July 24, it has set up an artificial intelligence (AI) precision diagnostic firm called NGeneBioAI.
NGeneBio formed this company to tap into the U.S. precision diagnosis market. The plan is to earmark the data-driven cancer genomic diagnostics market in the country through its own precision diagnostic software.
According to The Korea Economic Daily, the formation of NGeneBioAI was fully funded by NGeneBio, which is now standing as its parent company. Its US subsidiary is now expected to play a big role in NGeneBio’s entry into the region’s cancer diagnostics market. It will offer its next-generation sequencing (NGS) precision diagnostic platform as it starts to build its presence in the American market.
Moreover, in addition to services related to cancer data analysis, NGeneBio will also initiate healthcare data analysis technology. The company will create AI-based diagnostic software with the aim of commercializing data-driven early cancer diagnosis apparatus.
“NGENBIO’s precise diagnosis SW technology is being evaluated as excellent in performance and quality by clinicians to the extent that it is being used in clinical trials for cancer patients at domestic and foreign medical institutions,” NGeneBio’s chief executive officer, Choi Dae Chul explained in a press release.
The CEO added, “With the establishment of NGENBIO AI, we will increase the accuracy of cancer precision diagnosis by expanding NGENBIO SW to the US medical market, and speed up the ongoing strategic investment in the CLIA Lab to complete within the year.”
Finally, Korea Biomedical Review reported that the supply of the company’s NGS precision diagnosis product line will also start in earnest via partnership deals with Clinical Laboratory Improvement Amendments (CLIA) Labs in the U.S.
Photo by: NGeneBio Website
